Overview

Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This is an open label, multicenter, single-arm phase II trial with primary eqirubicine-oxaliplatin-capecitabine chemotherapy and concurrent Pmab in patients with resectable, histologically proven gastric or esophageal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Arbeitsgemeinschaft medikamentoese Tumortherapie

Collaborator:

Amgen

Treatments:

Antibodies, Monoclonal
Capecitabine
Epirubicin
Oxaliplatin
Panitumumab